OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Barrientos on Important Considerations for Patients with MCL

September 10th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses important considerations for patients with mantle cell lymphoma.

Dr. Locke on CAR T-Cell Therapy in NHL

September 10th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in HR+ Breast Cancer

September 10th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.

Dr. McCollum on Molecular Testing in CRC

September 10th 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses molecular testing in patients with colorectal cancer (CRC).

Dr. Figlin Discusses the Future of Kidney Cancer Treatment

September 10th 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.

Dr. Powell Discusses Data With Immunotherapy in Ovarian Cancer

September 8th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses data with immunotherapy in ovarian cancer.

Dr. Brander on the Treatment of Relapsed/Refractory CLL

September 8th 2018

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLC

September 8th 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Dr. Chavez on Blinatumomab in ALL

September 7th 2018

Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).

Dr. Brahmer on the IMpower150 Trial in NSCLC

September 7th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the clinical application of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Dr. Komrokji on the Changing Landscape of AML

September 7th 2018

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).

Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney Cancer

September 7th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Dr. Eyre on BTK Inhibitors in Combination With Venetoclax for MCL

September 7th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the potential for BTK inhibitors to be used in combination with venetoclax for mantle cell lymphoma.

Dr. Pinilla-Ibarz on the Role of Chemotherapy in CLL

September 7th 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Dr. Levy on Investigational Biomarkers of Response to Immunotherapy in NSCLC

September 7th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses investigational biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Agarwal on Next Steps in Kidney Cancer

September 7th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the next steps in the kidney cancer paradigm.

Dr. Balar Discusses Study of Immunotherapy Combination in Bladder Cancer

September 6th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses a study of an immunotherapy combination in bladder cancer.

Dr. Woodward on Regional Node Irradiation in Breast Cancer

September 6th 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses regional nodal irradiation for the treatment of patients with breast cancer.

Dr. Succaria on Targetable Immune Checkpoints in Head and Neck Cancer

September 6th 2018

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses targetable immune checkpoints in head and neck squamous cell carcinoma.

Dr. Kahl Discusses the Construction of ADCs for Lymphoma Treatment

September 6th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the construction of antibody-drug conjugates for the treatment of patients with lymphoma.